Prior use of GLP-1 medications does not disqualify you from bariatric surgery
The framework: Choose food when you can tolerate it and have room in your reduced calorie budget
Most causes for slow progress are manageable with provider support, and fluctuations in weight are normal parts of the tirzepatide journey
Participants receiving semaglutide demonstrated meaningful reductions in alcohol craving, drinks consumed per drinking day, and heavy drinking episodes compared with placebo
GLP-1 receptor agonists such as semaglutide (the active ingredient in Ozempic and Wegovy) are synthetic molecules that mimic these actions with much longer half-lives than the natural hormone
The study was terminated early by sponsor decision (not safety-related) after completing enrollment of 81 participants in May 2025, though specific efficacy results from this Phase 2 trial are not yet published, with prior Phase 1b data showing the 250mg dose achieved 49% reduction in total MS and clinical response in 8/11 patients versus 0/4 on placebo